REGN
Regeneron Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$827.72
−1.87%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
13.7x
EV/EBITDA
13.8x
Market Cap
$85.22B
MomentumView details →
1D Return
−1.87%
YTD Return
+8.12%
RSI (14)
62.9
ValuationView details →
P/E (Fwd)
13.7x
EV/EBITDA
13.8x
Market Cap
$85.22B
RSI (14)
62.9
MomentumView details →
1D Return
−1.87%
YTD Return
+8.12%
SummaryUpdated Jun 1, 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a leading biotechnology company founded in 1988 and headquartered in Tarrytown, New York. The company went public in 1991 and has evolved from a research-focused startup into one of the world's premier biotechnology companies. Regeneron discovers, develops, manufactures, and commercializes innovative medicines for serious diseases across multiple therapeutic areas including ophthalmology, immunology, oncology, and rare diseases. The company is known for its proprietary drug discovery platforms and has built a portfolio of blockbuster medicines that serve patients worldwide.
Similar companies
Latest newsMore news →
The Portnoy Law Firm announced a class action lawsuit against Regeneron Pharmaceuticals, Inc. on behalf of investors who bought securities between August 1, 2025 and May 15, 2026, alleging false statements during the Class Period.3d agoAllworth Financial LP acquired a new position of 2,530 shares in Regeneron Pharmaceuticals, Inc. during the second quarter, as disclosed in its 13F filing.14d agoA class action lawsuit was filed against Regeneron Pharmaceuticals, Inc. alleging violations of securities laws, and investors are being notified of their rights to seek lead plaintiff appointment.15d ago